| pubmed-article:2867207 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2867207 | lifeskim:mentions | umls-concept:C1280551 | lld:lifeskim |
| pubmed-article:2867207 | lifeskim:mentions | umls-concept:C0017067 | lld:lifeskim |
| pubmed-article:2867207 | lifeskim:mentions | umls-concept:C0027793 | lld:lifeskim |
| pubmed-article:2867207 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:2867207 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:2867207 | lifeskim:mentions | umls-concept:C0060180 | lld:lifeskim |
| pubmed-article:2867207 | lifeskim:mentions | umls-concept:C0733626 | lld:lifeskim |
| pubmed-article:2867207 | lifeskim:mentions | umls-concept:C0301625 | lld:lifeskim |
| pubmed-article:2867207 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:2867207 | pubmed:dateCreated | 1986-2-12 | lld:pubmed |
| pubmed-article:2867207 | pubmed:abstractText | This study was designed to determine the role of dopamine (DA) receptors in modulation of sympathetic ganglionic neurotransmission utilizing the selective DA-1 agonist fenoldopam. Preganglionic stimulation of cardiac sympathetic nerves (0.5-2.0 Hz), in pentobarbital anesthetized dogs, resulted in frequency-dependent tachycardia. Fenoldopam (10 and 30 micrograms/kg/min i.v.) suppressed the tachycardic response 45% at 0.5 Hz with no significant effect at higher stimulation frequencies. In the presence of SK&F 83566 (10 micrograms/kg/min i.v.), a selective DA-1 receptor antagonist, fenoldopam no longer elicited significant inhibition of the preganglionic response. When postganglionic cardiac nerves were stimulated (0.5 Hz), fenoldopam (100 micrograms/kg/min i.v.) inhibited the response 55% with no significant effect at lower doses. Stimulation of sympathetic preganglionic fibers in the autoperfused hindlimb of the dog induced vasoconstriction. Fenoldopam (3 micrograms/kg/min i.a.) produced marked inhibition of nerve-induced constriction that was partially antagonized by SK&F 83566 (3 micrograms/kg/min i.a.). Complete inhibition of the effect of fenoldopam on sympathetic nerve stimulation in the hindlimb could not be achieved, as a component of this action was apparently due to postjunctional alpha-2 adrenoceptor blockade. This was evidenced by a reduction in the pressor response to the selective alpha-2 adrenoceptor agonist B-HT 920 by fenoldopam. These data indicate that fenoldopam stimulates DA-1 receptors in sympathetic ganglia to inhibit neurotransmission and this effect can be reversed by a selective DA-1 receptor antagonist. | lld:pubmed |
| pubmed-article:2867207 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2867207 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2867207 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2867207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2867207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2867207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2867207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2867207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2867207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2867207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2867207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2867207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2867207 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2867207 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:2867207 | pubmed:issn | 0022-3565 | lld:pubmed |
| pubmed-article:2867207 | pubmed:author | pubmed-author:FujitaTT | lld:pubmed |
| pubmed-article:2867207 | pubmed:author | pubmed-author:HiebleJ PJP | lld:pubmed |
| pubmed-article:2867207 | pubmed:author | pubmed-author:BlumbergA LAL | lld:pubmed |
| pubmed-article:2867207 | pubmed:author | pubmed-author:ShebuskiR JRJ | lld:pubmed |
| pubmed-article:2867207 | pubmed:author | pubmed-author:SmithJ MJMJr | lld:pubmed |
| pubmed-article:2867207 | pubmed:author | pubmed-author:KopaciewiczL... | lld:pubmed |
| pubmed-article:2867207 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2867207 | pubmed:volume | 235 | lld:pubmed |
| pubmed-article:2867207 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2867207 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2867207 | pubmed:pagination | 735-40 | lld:pubmed |
| pubmed-article:2867207 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:meshHeading | pubmed-meshheading:2867207-... | lld:pubmed |
| pubmed-article:2867207 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:2867207 | pubmed:articleTitle | Suppression of sympathetic ganglionic neurotransmission by the selective dopamine-1 receptor agonist fenoldopam (SK&F 82526) in the anesthetized dog. | lld:pubmed |
| pubmed-article:2867207 | pubmed:publicationType | Journal Article | lld:pubmed |
